Clinical Trial Update: A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary [Phase 2]

View source ↗

Summary

Phase 2 trial assessing dual immune checkpoint inhibition with atezolizumab and tiragolumab in cancer of unknown primary; the study is active but not recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer of Unknown Primary

Drugs mentioned

• Atezolizumab (atezolizumab)
• Tiragolumab (tiragolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING